X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE LUPIN LTD SUVEN LIFE/
LUPIN LTD
 
P/E (TTM) x 19.8 20.3 97.4% View Chart
P/BV x 3.7 2.8 133.3% View Chart
Dividend Yield % 1.0 0.9 112.1%  

Financials

 SUVEN LIFE   LUPIN LTD
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
LUPIN LTD
Mar-17
SUVEN LIFE/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3391,750 19.3%   
Low Rs1441,384 10.4%   
Sales per share (Unadj.) Rs39.2387.4 10.1%  
Earnings per share (Unadj.) Rs7.556.6 13.2%  
Cash flow per share (Unadj.) Rs8.876.8 11.4%  
Dividends per share (Unadj.) Rs2.007.50 26.7%  
Dividend yield (eoy) %0.80.5 173.0%  
Book value per share (Unadj.) Rs49.0298.9 16.4%  
Shares outstanding (eoy) m127.28451.58 28.2%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.24.0 152.1%   
Avg P/E ratio x32.427.7 117.0%  
P/CF ratio (eoy) x27.520.4 134.9%  
Price / Book Value ratio x4.95.2 94.0%  
Dividend payout %26.813.2 202.4%   
Avg Mkt Cap Rs m30,732707,513 4.3%   
No. of employees `0001.016.8 5.7%   
Total wages/salary Rs m41628,495 1.5%   
Avg. sales/employee Rs Th5,236.110,418.3 50.3%   
Avg. wages/employee Rs Th436.51,697.0 25.7%   
Avg. net profit/employee Rs Th995.51,523.0 65.4%   
INCOME DATA
Net Sales Rs m4,995174,943 2.9%  
Other income Rs m1941,065 18.2%   
Total revenues Rs m5,189176,008 2.9%   
Gross profit Rs m1,23344,931 2.7%  
Depreciation Rs m1679,122 1.8%   
Interest Rs m541,525 3.6%   
Profit before tax Rs m1,20535,349 3.4%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2559,785 2.6%   
Profit after tax Rs m95025,575 3.7%  
Gross profit margin %24.725.7 96.1%  
Effective tax rate %21.227.7 76.5%   
Net profit margin %19.014.6 130.1%  
BALANCE SHEET DATA
Current assets Rs m4,986119,542 4.2%   
Current liabilities Rs m1,04261,206 1.7%   
Net working cap to sales %79.033.3 236.8%  
Current ratio x4.82.0 244.9%  
Inventory Days Days6176 80.3%  
Debtors Days Days3990 43.5%  
Net fixed assets Rs m3,126131,660 2.4%   
Share capital Rs m127903 14.1%   
"Free" reserves Rs m3,717134,073 2.8%   
Net worth Rs m6,236134,976 4.6%   
Long term debt Rs m43256,478 0.8%   
Total assets Rs m8,079266,073 3.0%  
Interest coverage x23.224.2 96.1%   
Debt to equity ratio x0.10.4 16.6%  
Sales to assets ratio x0.60.7 94.0%   
Return on assets %12.410.2 122.0%  
Return on equity %15.218.9 80.4%  
Return on capital %18.919.3 98.0%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,66681,885 5.7%   
Fx outflow Rs m94221,506 4.4%   
Net fx Rs m3,72460,378 6.2%   
CASH FLOW
From Operations Rs m92241,148 2.2%  
From Investments Rs m-619-25,287 2.4%  
From Financial Activity Rs m-6984,332 -16.1%  
Net Cashflow Rs m-39620,193 -2.0%  

Share Holding

Indian Promoters % 63.4 46.6 136.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.0 11.3 -  
FIIs % 0.0 31.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.1 361.4%  
Shareholders   37,287 98,259 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   ELDER PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  SUN PHARMA  IPCA LABS  

Compare SUVEN LIFE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 16, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS